36 Months Survivability And Its Predictors In Patients With Chronic Heart Failure And Decreased Fraction Of Left Ventricular Ejection Depending On Sex by Voronkov, L. (Leonid) et al.
Original Research Article:
full paper
(2017), «EUREKA: Health Sciences»
Number 5
44
Medicine and Dentistry
36 MONTHS SURVIVABILITY AND ITS PREDICTORS 
IN PATIENTS WITH CHRONIC HEART FAILURE AND 
DECREASED FRACTION OF LEFT VENTRICULAR 
EJECTION DEPENDING ON SEX 
Leonid Voronkov 
Department of heart failure
National Scientific Center “M. D. Strazhesko of NAMS of Ukraine”
5 Narodnogo Opolchennya str., Kyiv, Ukraine, 03151
Elena Filatova 
Department of heart failure
National Scientific Center “M. D. Strazhesko of NAMS of Ukraine”
5 Narodnogo Opolchennya str., Kyiv, Ukraine, 03151
Alina Lyashenko 
Department of heart failure
National Scientific Center “M. D. Strazhesko of NAMS of Ukraine”
5 Narodnogo Opolchennya str., Kyiv, Ukraine, 03151
Natalya Tkach 
Department of heart failure
National Scientific Center “M. D. Strazhesko of NAMS of Ukraine”
5 Narodnogo Opolchennya str., Kyiv, Ukraine, 03151
Pavel Babych 
State Expert Center of Ministry of Health of Ukraine
7 Grushevskogo str., Kyiv, Ukraine, 01601
Abstract
Aim of the work: to compare survivability parameters during 36 months and their predictors among men and women with 
chronic heart failure and decreased fraction of left ventricular ejection. 
Materials and methods: the research included 356 patients with CHF (NYHA ІІ–ІV) with decreased LVEF<40 %, 
18–75 years old. Using Kaplan-Meier method, there was analyzed the survivability in men and women during 36 months, then there 
were analyzed independent factors that influenced survivability terms depending on sex using the multiple logistic regression. 
Results. Our analysis of the survivability of patients with CHF with decreased LVEF demonstrated that the cumulative sur-
vival after 3 years of observation was 49 and 51 % for men and women, respectively. The curves of 36 months survivability didn’t 
reliably differ. At the analysis of factors, associated with the bad prognosis, there were observed differences between groups of men 
and women with CHF. Thus, in men the predictors of 36 month survival were: the thickness of the right ventricle wall, size of the 
right atrium, end-diastolic volume and end-systolic volume of LV, indices of EDV and ESV of LV, urinary acid level, value of LVEF. 
In women the predictors of survivability during 3 years were the following parameters: BMI, DM type 2 in an anamnesis, end-dia-
stolic size of LV, end-systolic size of LV, blood glucose level, LVEF. 
Conclusion. The survivability of men and women with CHF with decreased LVEF during 36 months didn’t reliably differ 
and was 49 and 51 % respectively. But predictors of the lethal outcome in men and women essentially differed during 36 months, and 
their number is essentially higher in men. 
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1. Introduction
Chronic heart failure (CHF) is the one of most unfavorable complications of cardio-vascular 
diseases in the prognostic aspect that has a tendency to the steady prevalence growth [1, 2]. Accord-
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ing to the data of epidemiologic studies, the prevalence of clinically expressed CHF (of II–IV func-
tional class in NYHA) in Ukraine is near 1 million people [3] Essential successes in decreasing 
mortality from CHF in developed countries were achieved mainly due to the introduction of mod-
ern methods of this syndrome treatment into practice and the progress in the care organization [4]. 
Last time works, devoted to differences of the clinical image and course of CHF depending on sex, 
appeared [5]. Thus, it was demonstrated, that MI was more seldom revealed in an anamnesis of wom-
en with CHF, arterial hypertension (AH) frequency and arterial pressure were higher at admission to 
hospital; in men were more often registered atrial fibrillation, ventricular premature beats, block of 
the right branch of His bundle [6]. There are also data that CHF of II FC was more often diagnosed 
in men, and among women – ІІІ FC according to NYHA [7]. There is observed also the quicker pro-
gression of CHF in men comparing with women [8]. The possibilities of individual prognostication of 
CHF course remain limited, because the main prognostic markers reflect patients’ survivability with-
out taking into account their sex [9]. So, the interest to gender aspects of CHF, including questions 
of clinical prognostication on cohorts of men and women taking into account prognosis-associated 
factors, essentially grows [10]. Based on it, the study of survivability predictors of patients with CFH 
and decreased left ventricular ejection fraction (LVEF) remains urgent. 
2. Aim of research
The comparison of parameters of 36 months survivability and their predictors among men 
and women with CHF and decreased LVEF. 
3. Materials and methods
The research included 356 patients with CHF (NYHA ІІ–ІV) with decreased LVEF<40 %, 
18–75 years old (mean age 62,0±8,0). Among them 259 men and 97 women, who were at the stationary 
treatment at the department of heart failure of MI “Institute of cardiology, named after M. D. Stargesk” 
NAMS of Ukraine in 2010–2013 with the further observation in the ambulatory group. The date of 
the first general clinical examination was taken As a start point of the observation. 88 % of examined 
patients had the concomitant arterial hypertension (AH), 241 (68 %) had the constant form of atrial 
fibrillation (AF), 111 (31 %) – myocardium infarction in an anamnesis (MI), 48 (13 %) – disorder of 
cerebral blood circulation in an anamnesis, 111 (31 %) – diabetes mellitus (DM) type 2, 82 (23 %) 
chronic obstructive pulmonary disease (COPD), 72 (20 %) – anemia of I degree.
The research didn’t include patients with valvular diseases, inflammatory heart lesion, acute 
ischemic heart disease (AIHD), stroke or transitory ischemic attack less 6 months, oncologic, en-
docrine (in particular, insulin-dependent DM), chronic, infectious diseases, and also nephrological 
disease (chronic pyelonephritis, chronic glomerulonephritis, renal amyloidosis). 
The diagnosis of the main disease was set on the base of the general clinic examination, 
special instrumental and laboratory research methods. CHF was diagnosed according to recom-
mendations of its diagnostics and treatment by the Association of cardiologists of Ukraine, agreed 
with analogous recommendations of the European community of cardiologists [11].
Obligatory methods of the examination of patients included: echocardiography, according 
to the standard method [12], routine electrocardiography, standard laboratory analyses (general 
clinic and biochemical), according to existent standards of diagnostics [10], realized on the base 
of the biochemical laboratory of MI “Institute of cardiology, named after M. D. Stargesk” NAMS 
of Ukraine. All patients underwent the treatment according to existent standards of the European 
community of cardiologists [11] that included: diuretics, beta-adrenoblockers, inhibitors of the an-
giotensin transforming enzyme (IATE) and others. 
The statistical processing of results was carried out using the package of applied programs 
SPSS 13.1 and Excel [13, 14]. The determination of independent factors, influencing patients’ 
survivability, was realized using Cox regression, survivability curves construction – by Ca-
plan-Meyer method, descriptive statistics methods [13, 14]. Independent survivability predictors 
were determined in each separately formed model. The significance level for statistical criteria 
was taken as 0,05.
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4. Results of research
Our analysis of survivability of patients with CHF with decreased LVEF demonstrated that 
the cumulative survival after 3 years of observation was 49 and 51 % for men and women, respec-
tively (р=0,137). The graph of the cumulative survival is presented on Fig. 1.
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Fig. 1. Survivability curves of patients with CHF and decreased LVEF during 36 months 
The search for 39 months survivability predictors depending on sex was carried out using 
Cox regression (univariant analysis). At the analysis of factors, associated with the bad prognosis, 
we observed essential differences between men and women with CHF. Thus, in men the predictors 
of 36 month survival were: the thickness of the right ventricle wall, size of the right atrium, end-di-
astolic volume and end-systolic volume of LV, indices of EDV and ESV of LV, urinary acid level, 
value of LVEF. As we can see on table 1 the most important were: the thickness of RV wall, RA 
size, LV ESVI value. 
Table 1
Survivability predictors in men with CHF and decrease LNEF during 36 months
Variable (covariant) Р-value OR β
95,0 % RI for OR
LL HL
RV wall thickness 0,039 1,524 0,421 1,021 2,275
RA size 0,012 1,660 0,507 1,115 2,471
LV ESVI 0,001 1,007 0,007 1,003 1,011
LV EDVI 0,039 1,004 0,004 1,000 1,007
LV ESV 0,002 1,003 0,003 1,001 1,005
LV EDV 0,051 1,002 0,002 1,000 1,003
Urinary acid level 0,007 1,001 0,001 1,000 1,002
LVEF 0,000 0,943 0,058 0,925 0,963
Note: LV ESV – end-systolic volume of the left ventricle. RV – right ventricle; LV EDV – end-diastolic volume of the left ventricle. 
RA – right atrium; EDVI – index of end-diastolic volume of the left ventricle; ESVI – index of end-systolic volume of the left ventricle; 
LVEF – left ventrical ejection fraction
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There was observed no statistically important influence on the survivability of such factors 
as: age, HF duration, MI in an anamnesis, body mass index (BMI), constant or persisting form of 
AF, thickness of left atrial walls, levels of glucose, cholesterol, creatitine of blood, speed of glo-
merular filtration. The presence of COPD or DM type 2 in an anamnesis also didn’t influence men’s 
survivability during 36 months. 
In women the predictors of the survivability during 3 years were the following parameters: 
BMI, DM type 2 in an anamnesis, end-diastolic size (EDS) of LV, end-systolic size (ESS) of LV, 
blood glucose level, end-systolic volume (ESV) of LV, end-diastolic volume (EDV) of LV, LVEF 
(Table 2). 
Table 2
Survivability predictors in women with CHF and decreased LVEF during 36 months
Variable (covariant) Р-value OR β
95,0 % RI for OR
LL HL
BMI 0,006 2,137 0,033 1,239 3,686
DM ІІ type 0,048 1,640 0,495 1,004 2,679
LV EDS 0,002 1,440 0,044 1,015 1,740
LV ESS 0,012 1,413 0,346 1,079 1,850
Blood glucose level 0,002 1,186 0,171 1,067 1,319
LV ESV 0,037 1,004 0,004 1,000 1,008
LV EDV 0,012 1,003 0,003 0,999 1,006
LVEF 0,000 0,941 0,061 0,910 0,972
Note: LV EDS – end-diastolic size of the left ventricle. LVEF – left ventricular ejection fraction; LV ESS end-systolic size of the left 
ventricle; BMI – body mass index; LV ESV – end-systolic volume of the left ventricle; DM – diabetes mellitus; LV EDV – end-diastolic 
volume of the left ventricle
Other factors had no reliable influence on women’s survivability during 36 months. 
5. Discussion of research results 
Due to numerous studies such as: Framingham Study, Nurses’ Health Study, Lipid Research 
Clinic Study, there was form an opinion as to the more favorable survivability prognosis among 
women with CHF [15]. At the same time, one must take into account that in aforesaid works was 
not usually considered HF type with decreased or preserved LVEF [16]. It must be supposed, that 
the better women’s survivability in these studies was obtained at the expanse of more number of 
individuals with CHF and preserved LVEF among them, that, on the one side prevails among wom-
en, on the other one is characterized with a better prognosis [17, 18]. Our analysis testifies that in 
the population of patients with CHF with decreased LVEF (<40 %) the prognosis of 3 year survival 
didn’t essentially differ depending on sex. At the same time there were revealed the differences 
of the lethal outcome occurrence in men and women that possibly must be taken into account at 
patients’ dispensary treatment. It’s interesting, that in male patients the leading predictors of the 
lethal outcome reflect the degree of heart remodeling (RV thickness, LV sizes, LV ESVI value). It 
is agreed with literary data about the more men’s inclination to dilatation and fibrosis formation 
[19, 20]. In women the most important lethal outcome predictors are the metabolism indicators 
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(BMI, DM in an anamnesis) that may be explained by more number of DM and pulmonary dys-
function cases among them comparing with men (41,6 % against 27,4 % р=0,012, and 60,8 % 
against 37,7 % р<0,001) respectively. The obtained data open the certain perspective for optimizing 
dispensary observation of this category of patients. 
6. Conclusions
1. The survival of men and women with CHF and decreased LVEF during 36 months didn’t 
reliably differ and was 49 and 51 % respectively. 
2. According to the results of Cox univariant model construction, the predictors of 3 year 
survival in men were: the thickness of the right ventricle wall, size of the right atrium, end-dia-
stolic volume and end-systolic volume of LV, indices of EDV and ESV of LV, urinary acid level, 
value of LVEF.
3. In women the predictors of survivability during 3 years were the following parameters: 
BMI, DM type 2 in an anamnesis, end-diastolic size of LV, end-systolic size of LV, blood glucose 
level, LVEF. 
4. The obtained results may be used for the optimization of dispensary observation of pa-
tients with CHF. 
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